Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Scott D SolomonJohn Joseph Valentine McMurrayMuthiah VaduganathanBrian ClaggettPardeep S JhundAkshay S DesaiAlasdair D HendersonCarolyn S P LamBertram PittMichele SenniSanjiv J ShahAdriaan A VoorsFaiez ZannadImran Zainal AbidinMarco Antonio Alcocer-GambaJohn J AthertonJohann BauersachsMa Chang-ShengChern-En ChiangOvidiu ChioncelVijay ChopraJosep Comin-ColetGerasimos FilippatosCândida FonsecaGrzegorz GajosSorel GolandEva GoncalvesovaSeokmin KangTzvetana KatovaMikhail N KosiborodGustavs LatkovskisAlex Pui-Wai LeeGerard C M LinssenGuillermo Llamas-EsperónVyacheslav MareevFelipe A MartinezVojtěch MelenovskýBela MerkelySavina NodariMark C PetrieClara Inés SaldarriagaJosé Francisco Kerr SaraivaNaoki SatoMorten SchouKavita SharmaRichard TroughtonJacob A UdellHeikki UkkonenOrly VardenySubodh VermaDirk von LewinskiLeonid VoronkovMehmet Birhan YilmazShelley ZierothJames Lay-FlurrieIlse van GamerenFlaviana AmarantePeter KolkhofPrabhakar Viswanathannull nullPublished in: The New England journal of medicine (2024)
In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).